Delaware
|
11-3516358
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(I.R.S. Employer Identification Number)
|
37000 Grand River Avenue, Suite 120
Farmington Hills, MI
|
48335
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
||
Common Stock, $0.0001 par value per share
|
|
OCUP
|
The Nasdaq Stock Market LLC
|
Large accelerated filer
|
☐ |
Non-accelerated filer
|
☒ |
Accelerated filer
|
☐ |
Smaller reporting company
|
☒ |
Emerging growth company
|
☐ |
Page
|
||
3 |
||
Item 1.
|
3 |
|
3 |
||
4 |
||
5 |
||
6 |
||
7 |
||
Item 2.
|
20 |
|
Item 3.
|
30 |
|
Item 4.
|
30 |
|
|
||
30 |
||
|
||
Item 1.
|
30 |
|
Item 1A.
|
30 |
|
Item 2.
|
31 |
|
Item 3.
|
31 |
|
Item 4.
|
31 |
|
Item 5.
|
31 |
|
Item 6.
|
31 |
|
|
||
32 |
Item 1. |
Financial Statements
|
As of
|
||||||||
March 31,
|
December 31,
|
|||||||
2024 | 2023 | |||||||
Assets
|
(unaudited) | |||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
47,161
|
$
|
50,501
|
||||
Accounts receivable |
1,924 | 926 | ||||||
Contract assets and unbilled receivables (Note 9) |
1,194 | 1,407 | ||||||
Prepaids and other assets
|
1,560 | 1,099 | ||||||
Short-term investments
|
5
|
15
|
||||||
Total current assets
|
51,844
|
53,948
|
||||||
Property and equipment, net
|
—
|
—
|
||||||
Total assets
|
$
|
51,844
|
$
|
53,948
|
||||
Liabilities and stockholders’ equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
2,064
|
$
|
2,153
|
||||
Accrued expenses
|
3,649
|
1,815
|
||||||
Derivative liability | 74 |
74 |
||||||
Total current liabilities
|
5,787
|
4,042
|
||||||
Total liabilities
|
5,787
|
4,042
|
||||||
Commitments and contingencies (Note 3 and Note 8)
|
|
|
||||||
Stockholders’ equity:
|
||||||||
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of March 31, 2024
and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023.
|
—
|
—
|
||||||
Common stock, par value $0.0001; 75,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 25,085,592
and 23,977,491 shares issued and outstanding at March 31, 2024 and December 31, 2023,
respectively.
|
3
|
2
|
||||||
Additional paid-in capital
|
134,626
|
131,370
|
||||||
Accumulated deficit
|
(88,572
|
)
|
(81,466
|
)
|
||||
Total stockholders’ equity
|
46,057
|
49,906
|
||||||
Total liabilities and stockholders’ equity
|
$
|
51,844
|
$
|
53,948
|
|
Three Months Ended
March 31,
|
|||||||
2024
|
2023
|
|||||||
License and collaborations revenue |
$ | 1,711 | $ | 1,749 | ||||
Operating expenses:
|
||||||||
General and administrative
|
4,670
|
2,285
|
||||||
Research and development
|
4,749
|
5,595
|
||||||
Total operating expenses
|
9,419
|
7,880
|
||||||
Loss from operations |
(7,708
|
)
|
(6,131
|
)
|
||||
Fair value change in derivative liabilities |
— | — | ||||||
Other income, net
|
602
|
340
|
||||||
Loss before income taxes
|
(7,106
|
)
|
(5,791
|
)
|
||||
Benefit (provision) for income taxes
|
—
|
—
|
||||||
Net loss |
(7,106
|
)
|
(5,791
|
)
|
||||
Other comprehensive loss, net of tax |
—
|
—
|
||||||
Comprehensive loss |
$
|
(7,106
|
)
|
$
|
(5,791
|
)
|
||
Net loss per share: | ||||||||
Basic and diluted (Note 10)
|
$
|
(0.29
|
)
|
$
|
(0.28
|
)
|
||
Number of shares used in per share calculations:
|
||||||||
Basic and diluted
|
24,520,475
|
20,939,607
|
Common Stock
|
Additional
Paid–In
|
Accumulated
|
Total
|
|||||||||||||||||
Shares
|
Amount
|
Capital
|
Deficit
|
Equity
|
||||||||||||||||
Balance at December 31, 2022
|
20,861,315
|
$
|
2
|
$
|
117,717
|
$
|
(71,480
|
)
|
$
|
46,239
|
||||||||||
Issuance costs | — | — | (2 | ) | — | (2 | ) | |||||||||||||
Stock–based compensation
|
68,646
|
—
|
804
|
—
|
804
|
|||||||||||||||
Exercise of warrants |
17,869 | — | — | — | — | |||||||||||||||
Net and comprehensive loss
|
—
|
—
|
—
|
(5,791
|
)
|
(5,791
|
)
|
|||||||||||||
Balance at March 31, 2023
|
20,947,830
|
$
|
2
|
$
|
118,519
|
$
|
(77,271
|
)
|
$
|
41,250
|
Common Stock |
Additional
Paid–In
|
Accumulated | Total | |||||||||||||||||
Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
Balance at December 31, 2023
|
23,977,491
|
$
|
2
|
$
|
131,370
|
$
|
(81,466
|
)
|
$
|
49,906
|
||||||||||
Issuance
of common stock in connection with the at-the-market program and purchase agreement |
1,000,550 | 1 | 2,478 | — | 2,479 | |||||||||||||||
Issuance costs
|
— | (165 | ) | — | (165 | ) | ||||||||||||||
Stock–based compensation
|
120,516
|
—
|
985
|
—
|
985
|
|||||||||||||||
Share repurchases for the payment of employee taxes |
(12,965 | ) | — | (42 | ) | — | (42 | ) | ||||||||||||
Net and comprehensive loss
|
—
|
—
|
—
|
(7,106
|
)
|
(7,106
|
)
|
|||||||||||||
Balance at March 31, 2024
|
25,085,592
|
$
|
3
|
$
|
134,626
|
$
|
(88,572
|
)
|
$
|
46,057
|
Three Months Ended
March 31,
|
||||||||
2024
|
2023
|
|||||||
Operating activities
|
||||||||
Net loss
|
$
|
(7,106
|
)
|
$
|
(5,791
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Stock-based compensation
|
985
|
804
|
||||||
Depreciation
|
—
|
1
|
||||||
Fair value change in derivative liabilities
|
— | — | ||||||
Unrealized loss from short-term investments
|
10 | 27 | ||||||
Change in assets and liabilities:
|
||||||||
Accounts receivable
|
(998 | ) | (1,536 | ) | ||||
Contract assets and unbilled receivables
|
213 | 1,085 | ||||||
Prepaid expenses and other assets
|
(461
|
)
|
365
|
|||||
Accounts payable
|
(89
|
)
|
1,152
|
|||||
Accrued expenses
|
1,730
|
247
|
||||||
Net cash used in operating activities
|
(5,716
|
)
|
(3,646
|
)
|
||||
Investing activities
|
||||||||
Net cash used in investing activities
|
—
|
—
|
||||||
Financing activities
|
||||||||
Proceeds from issuance of common stock in connection with the at-the-market program and purchase agreement
|
2,479 | — | ||||||
Issuance costs | (61 | ) | — | |||||
Share repurchases for the payment of employee taxes |
(42 | ) | — | |||||
Net cash provided by financing activities
|
2,376
|
—
|
||||||
Net decrease in cash and cash equivalents
|
(3,340
|
)
|
(3,646
|
)
|
||||
Cash and cash equivalents at beginning of period
|
50,501
|
42,634
|
||||||
Cash and cash equivalents at end of period
|
$
|
47,161
|
$
|
38,988
|
||||
Supplemental disclosure of cash flow information:
|
||||||||
Cash paid for income taxes
|
$
|
—
|
$
|
—
|
||||
Cash paid for interest
|
$
|
—
|
$
|
—
|
||||
Supplemental non-cash financing transactions:
|
||||||||
Unpaid issuance costs |
$
|
104
|
$
|
2
|
1. |
Company Description and Summary of Significant Accounting Policies
|
|
● |
Level 1 inputs: Unadjusted quoted prices for identical assets or liabilities in active markets;
|
|
● |
Level 2 inputs: Quoted prices for similar assets and liabilities in active markets, quoted prices in
markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the asset or liability; and
|
|
● |
Level 3 inputs: Unobservable inputs in which there is little or no market data available, which
requires management to develop its own assumptions in pricing the asset or liability.
|
As of March 31, 2024
|
||||||||||||||||
Description
|
Total
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Assets:
|
||||||||||||||||
Short-term investments |
$
|
5
|
$
|
5
|
$
|
—
|
$
|
—
|
||||||||
Total assets at fair value
|
$
|
5
|
$
|
5
|
$
|
—
|
$
|
—
|
||||||||
Liabilities: | ||||||||||||||||
Derivative liability | $ |
74 | $ |
— | $ |
— | $ |
74 | ||||||||
Total liabilities at fair value | $ |
74 | $ |
— | $ |
— | $ |
74 |
As of December 31, 2023
|
||||||||||||||||
Description
|
Total
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Assets:
|
||||||||||||||||
Short-term investments
|
$
|
15
|
$
|
15
|
$
|
—
|
$
|
—
|
||||||||
Total assets at fair value
|
$
|
15
|
$
|
15
|
$
|
—
|
$
|
—
|
||||||||
Liabilities: |
||||||||||||||||
Derivative liability |
$ |
74 | $ |
— | $ |
— | $ |
74 | ||||||||
Total liabilities at fair value |
$ |
74 | $ |
— | $ |
— | $ |
74 |
Three Months Ended
March 31,
|
||||||||
2024
|
2023
|
|||||||
Short-term investments
|
||||||||
Balance as of beginning of period
|
$
|
15
|
$
|
49
|
||||
Unrealized loss
|
(10
|
)
|
(27
|
)
|
||||
Balance as of end of period
|
$
|
5
|
$
|
22
|
Three Months Ended March 31,
|
||||||||
2024
|
2023
|
|||||||
Derivative liabilities
|
||||||||
Balance as of beginning of period
|
$
|
74
|
$
|
—
|
||||
Change in fair value of derivative liabilities
|
—
|
—
|
||||||
Balance as of end of period
|
$ | 74 |
$
|
—
|
2. |
Merger
|
|
● |
90% of all
payments received by Rexahn or its affiliates during such CVR Payment Period from or on behalf of BioSense Global LLC (“BioSense”) pursuant to that certain License and Assignment Agreement, dated as of February 25, 2019, by and
between BioSense and Rexahn, as amended by Amendment No. 1, dated August 24, 2019, and as further amended by Amendment No. 2, dated March 10, 2020, minus certain permitted deductions;
|
|
● |
90% of all
payments received by Rexahn or its affiliates during such CVR Payment Period from or on behalf of Zhejiang HaiChang Biotechnology Co., Ltd. (“HaiChang”) pursuant to that certain Exclusive License Agreement, dated as of February
8, 2020, by and between HaiChang and Rexahn, minus certain permitted deductions; and
|
|
● |
75% of the sum
of (i) all cash consideration paid by a third party to Rexahn or its affiliates during the applicable CVR Payment Period in connection with the grant, sale or transfer of rights to Rexahn’s pre-closing intellectual property
(other than a grant, sale or transfer of rights involving a sale or disposition of the post-Merger combined company) that is entered into during the 10-year
period after the closing (“Parent IP Deal”), plus (ii) with respect to any non-cash consideration received by Rexahn or its affiliates from a third party during the applicable CVR Payment Period in connection with any Parent IP
Deal, all amounts received by Rexahn or its affiliates for such non-cash consideration at the time such non-cash consideration is monetized by Rexahn or its affiliates, minus (iii) certain permitted deductions.
|
3.
|
Commitments and Contingencies
|
4. |
Supplemental Balance Sheet Information
|
March 31,
2024
|
December 31,
2023
|
|||||||
Prepaids
|
$
|
1,471
|
$
|
997
|
||||
Other
|
89
|
102
|
||||||
Total prepaids and other assets
|
$
|
1,560
|
$
|
1,099
|
March 31,
2024
|
December 31,
2023
|
|||||||
Equipment
|
|
20
|
$
|
20
|
||||
Furniture
|
5
|
5
|
|
|||||
Total property and equipment
|
|
25
|
|
25
|
||||
Less accumulated depreciation
|
(25
|
)
|
(25
|
)
|
||||
Property and equipment, net
|
$
|
—
|
$
|
—
|
March 31,
|
December 31,
|
|||||||
2024
|
2023
|
|||||||
Payroll
|
$ |
427
|
$ |
753
|
||||
Professional services
|
1,630
|
591
|
||||||
Research and development services and supplies
|
1,497 | 400 | ||||||
Other
|
95
|
71
|
||||||
Total
|
$ |
3,649
|
$
|
1,815
|
5. |
Related Party Transactions
|
6. |
Stockholders’ Equity
|
|
• |
the lowest sale price for the Company’s common stock on Nasdaq
on the purchase date of such shares; and
|
|
• |
the average of the three lowest closing sale prices for the
Company’s common stock on Nasdaq during the ten consecutive business days prior to the purchase date of such shares.
|
|
• |
three times the number of shares purchased pursuant to such Regular Purchase; and
|
|
• |
30% of the aggregate shares of the Company’s common stock traded on Nasdaq during all or, if certain trading volume or market price thresholds specified in
the Purchase Agreement are crossed on the applicable Accelerated Purchase date, the portion of the normal trading hours on the applicable Accelerated Purchase date prior to such time that any one of such thresholds is crossed
(the “Accelerated Purchase Measurement Period”).
|
|
• |
the closing sale price of the Company’s common stock on Nasdaq
on the applicable Accelerated Purchase date; and
|
|
• |
the volume-weighted average price of the Company’s common
stock on Nasdaq during the applicable Accelerated Purchase Measurement Period on the applicable Accelerated Purchase date.
|
7. |
Stock-based Compensation
|
March 31,
|
||||||||
2024
|
2023
|
|||||||
General and administrative
|
$
|
775
|
$
|
468
|
||||
Research and development
|
210
|
336
|
||||||
Total stock-based compensation
|
$
|
985
|
$
|
804
|
2024
|
2023
|
|||||||
Expected stock price volatility
|
97.5
|
%
|
95.4
|
%
|
||||
Expected life of options (years)
|
6.1
|
6.1
|
||||||
Expected dividend yield
|
—
|
% |
—
|
%
|
||||
Risk free interest rate
|
4.1
|
%
|
3.7
|
%
|
8. |
Apexian Sublicense Agreement
|
9.
|
License and Collaboration Agreements
|
Three Months Ended
March 31,
|
||||||||
2024 | 2023 |
|||||||
Contract
Assets and Unbilled Receivables
|
|
|
||||||
Balance as of beginning of three-month period
|
$
|
1,407
|
$ |
3,552 | ||||
Revenue recognized
|
1,711
|
1,749 | ||||||
Reclassification to accounts receivable related to costs billed under the Viatris License Agreement
|
(1,924
|
)
|
(2,834 | ) | ||||
Balance as of end of three-month period
|
$
|
1,194
|
$ |
2,467 |
10. |
Net loss per share
|
March 31,
|
||||||||
2024
|
2023
|
|||||||
Series A and RDO warrants
|
7,204,299
|
7,204,299
|
||||||
Stock options
|
4,827,433
|
3,601,427
|
||||||
RSUs | 993,112 | 291,584 | ||||||
Former Rexahn warrants
|
—
|
60,713
|
11.
|
Income Taxes
|
12.
|
Deferred Compensation Plan
|
13. |
Subsequent Events
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
|
• |
The success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts;
|
|
• |
Regulatory requirements or developments;
|
|
• |
Changes to or unanticipated events in connection with clinical trial designs and regulatory pathways;
|
|
• |
Delays or difficulties in the enrollment of patients in clinical trials;
|
|
• |
Substantial competition and rapid technological change;
|
|
• |
Our development of sales and marketing infrastructure;
|
|
• |
Future revenue losses and profitability;
|
|
• |
Our relatively short operating history;
|
|
• |
Changes in capital resource requirements;
|
|
• |
Risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs;
|
|
• |
Domestic and worldwide legislative, regulatory, political and economic developments;
|
|
• |
Employee misconduct;
|
|
• |
Changes in market opportunities and acceptance;
|
|
• |
Reliance on third-parties;
|
|
• |
Future, potential product liability and securities litigation;
|
|
• |
System failures, unplanned events, or cyber incidents;
|
|
• |
The substantial number of shares subject to potential issuance associated with our Equity Line of Credit arrangement with Lincoln Park Capital Fund, LLC;
|
|
• |
Risks that our partnership with Viatris, or our other licensing arrangements, may not facilitate the commercialization or market acceptance of Ocuphire’s product candidates;
|
|
• |
Future fluctuations in the market price of our common stock;
|
|
• |
The success and timing of commercialization of any of Ocuphire’s product candidates; and
|
|
• |
Obtaining and maintaining Ocuphire’s intellectual property rights.
|
|
• |
continue clinical trials for APX3330, PS and for any other product candidate in our future pipeline;
|
|
• |
continue nonclinical studies for APX3330, APX2009 and APX2014, PS and for any other product candidate in our future pipeline;
|
|
• |
develop additional product candidates that we identify, in-license or acquire;
|
|
• |
seek regulatory approvals for any product candidates that successfully complete clinical trials;
|
|
• |
contract to manufacture our product candidates;
|
|
• |
maintain, expand and protect our intellectual property portfolio;
|
|
• |
hire additional staff, including clinical, scientific, operational and financial personnel, to execute our business plan;
|
|
• |
add operational, financial and management information systems and personnel to support our product development and potential future commercialization efforts;
|
|
• |
continue to operate as a public company; and
|
|
• |
establish on our own or with partners, a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval.
|
For the Three Months Ended
March 31,
|
||||||||||||
2024
|
2023
|
Change | ||||||||||
License and collaborations revenue
|
$
|
1,711
|
$
|
1,749
|
$
|
(38
|
)
|
|||||
Operating expenses:
|
||||||||||||
General and administrative
|
4,670
|
2,285
|
2,385
|
|||||||||
Research and development
|
4,749
|
5,595
|
(846
|
)
|
||||||||
Total operating expenses
|
9,419
|
7,880
|
1,539
|
|||||||||
Loss from operations
|
(7,708
|
) |
(6,131
|
) |
(1,577
|
)
|
||||||
Fair value change in derivative liabilities
|
—
|
—
|
—
|
|||||||||
Other income, net
|
602
|
340
|
262
|
|||||||||
Loss before income taxes
|
(7,106
|
) |
(5,791
|
) |
(1,315
|
)
|
||||||
Provision for income taxes
|
—
|
—
|
—
|
|||||||||
Net loss
|
$
|
(7,106
|
) |
$
|
(5,791
|
) |
$
|
(1,315
|
)
|
For the Three Months Ended
March 31,
|
||||||||||||
2024
|
2023
|
Change
|
||||||||||
External costs:
|
||||||||||||
Phentolamine Ophthalmic Solution 0.75% (“PS”)
|
$
|
1,065
|
$
|
3,801
|
$
|
(2,736
|
)
|
|||||
APX 3330
|
2,663
|
886
|
1,777
|
|||||||||
Unallocated
|
67
|
198
|
(131
|
)
|
||||||||
Total external cost
|
3,795
|
4,885
|
(1,090
|
)
|
||||||||
Internal costs:
|
||||||||||||
Employee related expenses
|
937
|
707
|
230
|
|||||||||
Facilities, supplies and other
|
17
|
3
|
14
|
|||||||||
Total internal costs
|
954
|
710
|
244
|
|||||||||
Total research and development expenses
|
$
|
4,749
|
$
|
5,595
|
$
|
(846
|
)
|
For the Three Months Ended
March 31,
|
||||||||
2024
|
2023 | |||||||
Net cash used in operating activities
|
$
|
(5,716
|
)
|
$
|
(3,646
|
)
|
||
Net cash provided by (used in) investing activities
|
—
|
—
|
||||||
Net cash provided by financing activities
|
2,376
|
—
|
||||||
Net decrease in cash and cash equivalents
|
$
|
(3,340
|
)
|
$
|
(3,646
|
)
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk
|
Item 4. |
Controls and Procedures
|
Item 1. |
Legal Proceedings
|
Item 1A. |
Risk Factors
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds
|
Item 3. |
Defaults Upon Senior Securities
|
Item 4. |
Mine Safety Disclosures
|
Item 5. |
Other Information
|
Item 6. |
Exhibits
|
EXHIBIT
|
||
NUMBER
|
|
DESCRIPTION OF DOCUMENT
|
Third Amendment to the Consulting Agreement, dated as of January 1, 2024, by and between the Company and Jay Pepose, M.D.
|
||
Employment Agreement, dated as of February 13, 2024, by and between the Company and Nirav Jhaveri (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 16, 2024).
|
||
First Amendment to Employment Agreement, dated as of February 16, 2024, by and between the Company and Nirav Jhaveri (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on February 16, 2024).
|
||
Consulting Agreement, dated as of April 11, 2024, by and between the Company and Jay Pepose, M.D. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on April 17, 2024).
|
||
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
101.INS**
|
Inline XBRL Instance Document.
|
|
101.SCH**
|
Inline XBRL Taxonomy Extension Schema Document.
|
|
101.CAL**
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
101.DEF**
|
Inline XBRL Taxonomy Extension Definition Linkbase Document.
|
|
101.LAB**
|
Inline XBRL Taxonomy Extension Label Linkbase Document.
|
|
101.PRE**
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
104**
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
+
|
Indicates management contract or compensatory plan.
|
*
|
Documents are furnished not filed.
|
**
|
Filed herewith. |
By:
|
/s/ George Magrath
|
|
George Magrath
|
||
Chief Executive Officer and Director
|
||
(Principal Executive Officer)
|
||
By:
|
/s/ Nirav Jhaveri
|
|
Nirav Jhaveri
|
||
Chief Financial Officer
|
||
(Principal Financial Officer)
|
By:
|
/s/ Amy Rabourn
|
|
Amy Rabourn
|
||
Senior Vice President of Finance
|
||
(Principal Accounting Officer)
|
CONSULTANT: |
|
THE COMPANY: |
|||
|
|
|
|
|
|
|
|
|
Ocuphire Pharma, Inc.
|
||
|
|
|
|
|
|
By: |
/s/ Jay S. Pepose, M.D.
|
|
By: |
/s/ Bernhard Hoffmann
|
|
Jay S. Pepose, M.D. |
|
Bernhard Hoffmann |
|
||
|
4/2/2024
|
|
SVP - Corporate Development |
|
|
|
|
|
|
4/2/2024
|
|
Date: May 10, 2024
|
/s/ George Magrath
|
|
|
Name:
|
George Magrath
|
|
Title:
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
Date: May 10, 2024
|
/s/ Nirav Jhaveri
|
|
|
Name:
|
Nirav Jhaveri |
|
Title:
|
Chief Financial Officer |
|
|
(Principal Financial Officer) |
/s/ George Magrath
|
|
George Magrath
|
|
Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
/s/ Nirav Jhaveri
|
|
Nirav Jhaveri
|
|
Chief Financial Officer
|
|
(Principal Financial Officer)
|
|
|
|
Dated: May 10, 2024
|
|